Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel(®) given by either self/partner or a health care professional.

Johanson, Viktor; Wilson, Benedicte; Abrahamsson, Anna; Jianu, Constantin; Calissendorff, Jan; Wall, Najme; Grønbæk, Henning; Florholmen, Jon; Ohberg, Anders; Granberg, Dan

Johanson, Viktor; Wilson, Benedicte; Abrahamsson, Anna; Jianu, Constantin; Calissendorff, Jan; Wall, Najme; Grønbæk, Henning; Florholmen, Jon; Ohberg, Anders; Granberg, Dan.

Affiliation

Johanson V; Department of Surgery, Sahlgrenska University Hospital, Göteborg, Sweden.

Patient Prefer Adherence ; 6: 703-10, 2012.

Article in En | MEDLINE | ID: mdl-23118529

Key words

carcinoid syndrome; lanreotide; neuroendocrine tumors; self administration; somatostatin analogs

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Aspects: Patient_preference Language: En Journal: Patient Prefer Adherence Year: 2012 Document type: Article Affiliation country: Sweden Country of publication: New Zealand

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google